SOME PECULIARITIES OF THE TREATMENT OF ISCHEMIC HEART DISEASE IN WOMEN. PART 1

Petrov Ye. Ye., Kazakov Yu. M., Treumova S. I., Burmak Yu. G.

LITERATURE REVIEWS

Scentific article

The influence of gender anatomical and physiological peculiarities upon pharmacokinetics and pharmacodynamics of medicaments and also particulars of using of antianginal and antiplatelet drugs among women with ischemic heart disease (IHD) are presented in the review. Inversely proportional dependence between the amount of beta-adrenoreceptor and level of estrogens was revealed experimentally. Theoretically it can lead to higher effectiveness of beta-blockers (BB) among women. Gender distinctions of pharmacokinetic properties between cardiocelective and non-celective BB were established. BB are the medicaments of the choice among women, taking into account often microcircular type of IHD among them. In relation to effectiveness of BB (metoprolol was studied) for prevention of acute coronary pathology, reasons for the conclusion about differences of the latter among men and women are absent. Any gender distinctions in the level of mortality (the same decrease) after myocardial infarction (MI) in case of metoprolol’s using weren’t marked. The main clinical studies concerning the using of BB after old MI with a purpose of the secondary prophylaxis showed contradictory results in relation to specific gender differences. Results of pharmacokinetic study established essential gender distinctions in action of some calcium antagonists (CA), of nifedipine and verapamil (in case of intravenous introduction) particularly. Pharmacodynamic gender differences of CA are insignificant. The favorable influence of CA upon the course of atherosclerosis among women (prevention of new atherosclerotic plaques’ development) is supposed to be, the facts of the prognosis’s improvement for patients with angina pectoris in case of regular using of CA are present. Only prolonged drug dosage form or long-acting new generations of CA from dehydropyridines derivatives are recommended for a long treatment of IHD among women. CA are indicated for the treatment of vasospastic (variant) angina pectoris particularly. Now data about gender pharmacokinetic and pharmacodynamics differences in case of nitrates’ using are absent. Only isolated information about more frequent registration of headache among women with IHD in case of using of nitrates is present. Now it is well-known that pharmacokinetics of acetylsalicylic acid (ASA) has gender differences. Researches showed that an effect of using of ASA with a purpose of the secondary prophylaxis of female and male IHD is comparable on the whole. But the data concerning the effectiveness of ASA for the primary prophylaxis were scantier and the question is disputable till now. Totally the using of low doses of ASA for the secondary prophylaxis of IHD and also for the primary and secondary prophylaxis of acute coronary syndrome among persons with stable forms of IHD is reasonable and effective. It is confirmed by some studies. The recommendations of ESC 2013 propose clopidogrel for prophylaxis of cardiovascular complications in case of ASA intolerance. Researches have showed that the protective effect of clopidogrel is comparable among the both sexes, but frequency of bleeding was higher among women. Concerning the using of antiplatelet drugs and IIb/IIIa receptors inhibitors after coronary interventions, it was marked that the frequency of hemorrhagic complications is higher among women. It testifies about necessities of correction of standard doses (consideration of body weight for amendment). Coronary thrombolysis is prescribed for women with IHD more seldom, many researches connect this fact with older age of women and their later appeal for medical aid. Medication revascularization has less final advantages among women than among men. Thrombolytic therapy is effective and safe among young women.

ischemic heart disease, women, treatment

• 1. Барна О. Н. Гендерные аспекты лечения ишемической болезни сердца / О. Н. Барна // Новости медицины и фармации. — 2009. — № 274. — С. 84-89.
• 2. Бугаенко В. В. Гендерные особенности диагностики, течения и лечения ишемической болезни сердца / В. В. Бугаенко, И. П. Голикова, М. Ю. Шеремет // Рациональная фармакотерапия. — 2015. — № 1. — С 5-19.
• 3. Волков В. И. Особенности диагностики и лечения ишемической болезни сердца у женщин / В. И. Волков, А. С. Исаева // Ліки України. — 2009. — № 1. — С. 57-63.
• 4. Гуревич М. А. Особенности клинического течения и лечения ишемической болезни сердца у женщин / М. А. Гуревич, Л. В. Архипова // CONSILIUM MEDICUM UKRAINA. — 2011. — № 5. — С. 34-39.
• 5. Дворецкий Л. И. Ишемическая болезнь сердца у женщин / Л. И. Дворецкий, Н. Т. Гибрадзе, Н. А. Черкасова // Русский медицинский журнал. — 2011. — № 2. — С. 79-84.
• 6. Корягина Н. А. Эффективность небивалола при лечении женщин с ишемической болезнью сердца / Н. А. Корякина, А. В. Петрищева // Российский кардиологический журнал. — 2014. — № 12. — С. 71-75.
• 7. Лавин Н. Эндокринология / Ред. Н. Левин; Пер. с англ. В. И. Кандрора, Э. А. Антуха, Т. Г. Горлиной; Ред. пер. А. В. Тимофеев. — М.: Практика, 1999. — 1128 с.
• 8. Лутай М. І. Добова антигіпертензивна ефективність амлодипіну та фелодипіну у пацієнтів з ішемічною хворобою серця, поєднаною з артеріальною гіпертензією/ М. І. Лутай, В. М. Ванджура // Український кардіологічний журнал. — 2000. — № 5, 6. — С. 30-33.
• 9. Максимов М. Л. Особенности клинического течения и фармакотерапии ИБС у женщин. Первые результаты фармакоэпидемиологического исследования ИБС у пациентов Московского региона / М. Л. Максимов, О. В. Дралова, В. Л. Купрейчик // Качественная клиническая практика. — 2008. — № 3. — C. 56-59.
• 10. Оганов Р. Г. Гендерные различия кардиоваскулярной патологии / Р. Г. Оганов, Г. Я. Масленникова // Кардиоваскулярная терапия и профилактика. — 2012. — № 11. — С. 101-104.
• 11. Рекомендации по лечению стабильной ишемической болезни сердца ESC 2013 // Российский кардиологический журнал. — 2014. — № 7. — С. 7-79.
• 12. Baigent C. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials / C. Baigent , L. Blackwell, R. Collins [et al.] // Lancet. — 2009. — Vol. 373, Issue 9678. – P. 1849-1860.
• 13. Becker R. C. Comparison of clinical outcomes for women and men after acute myocardial infarction / R. S. Becker, M. Terrin, R. Ross // Ann. Intern. Med. — 1994. — Vol. 120. — P. 638-645.
• 14. Berger J. S. The relative safety and efficacy of clopidogrel in women and men: meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA / J. S. Berger, D. L. Bhatt, C. P. Cannon [et al.] // Circ. — 2007. — Vol. 116. — P. 483-489.
• 15. Cavallari L. H. Sex difference in the antiplatelet effect of aspirin in patients with stroke / L. H. Cavallari, C. M. Helgason, L. D. Brace [et al.] // Ann. Pharmacother. — 2006. — Vol. 40, N 5. — P. 812-817.
• 16. Clayton T. C. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial / T.C. Clayton, S. J. Pocock, R. A. Henderson // Eur. Heart J. — 2004. — Vol. 25. — P. 1641-1650.
• 17. Cotreau M. M. The influence of age and sex on the clearance of cytochrome P450 ЗА substrates / M. M. Cotreau, L. L. von Moltke, D. J. Greenblatt // Clin. Pharmacokinet. — 2005. — Vol. 44. — P. 33-60.
• 18. Flather M. D. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) / M. D. Flather, M. C. Shibata, A. J. Coats [et al.] // Eur. Heart J. — 2005. — Vol. 26, N 3. — P. 215-225.
• 19. Gilmore D. A. Age and gender influence the stereoselective pharmacokinetics of propranolol / D. A. Gilmore, J. Gal, J. G. Gerber, A. S. Nies // J. Pharmacol. Exp. Ther. — 1992. — Vol. 261, N 3. — P. 1181-1186.
• 20. Hsi D. H. Headache response to glyceryl trinitrate in patients with and without obstructive coronary artery disease / D. H. Hsi, A. Roshandel, N. Singh [et al.] // Heart. — 2005. — Vol. 91, N 9. — P. 1164-1166.
• 21. Isaacsohn J. Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults / J. Isaacsohn, M. Zinny, A. Mazzu, J. Lettieri // Eur. J. Clin. Pharmacol. — 2001. — Vol. 56. — P. 897-903.
• 22.Jochmann N. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases / N. Jochmann, K.Stangl, E.Garbe [et al.] // Eur. Heart. J. — 2005. — Vol. 26, N16. — P. 1585-1595.
• 23. Kjeldsen S.E. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study/ S.E. Kjeldsen, T. Hedner, J.O. Syvertsen [et al.] // J. Hypertens. — 2002. — Vol. 20. — P. 1231-1237.
• 24. Kloner R. Sex- and age-related Antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial study group / R. Kloner, L. Sowers, G. DiBona [et al.] // Amer. J. Cardiol. — 1996. — Vol. 77, N 9. — P. 713-722.
• 25. Lansky A.J. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association / A.J. Lansky, J.S. Hochman, P.A Ward [et al.] // Circulation. — 2005. — Vol. 111, N7. — P. 940-953.
• 26. Luzier A.B. Gender-related effects on metoprolol pharmacokinetics and pharmaco dynamics in healthy volunteers/ A.B. Luzier, A. Killian, J.H. Wilton, M.F. Wilson// Clin. Pharmacol. Ther. — 1999. — Vol. 66, N6. — P. 594-601.
• 27. Meibohm B. How important are gender differences in pharmacokinetics/ B. Meibohm, I. Beierle, H.Derendorf // Clin. Pharmacokinet. — 2002. — Vol. 41, N5. — P. 329-342.
• 28. Mendelsohn M.E. Molecular and cellular basis of cardiovascular gender differences. Review / M.E. Mendelsohn, R.H. Karas// Science. — 2005. —Vol. 308, N 10. — P. 1583-1587.
• 29. Negishi E. Surveillance study about the use actual of prescription drugs from the viewpoint of gender / E. Negishi, Y. Domon, M. Ueda [et al.] // Yakugaku Zasshi. — 2005. — Vol. 125, N10. — P. 821-827.
• 30. Ridker P. M. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women / P. M. Ridker, N. R. Cook, I. - M. Lee [et al.] // N. Engl. J. Med. — 2005. — Vol. 352, N 13. — P. 1293-1304.
• 31. Schaefer B.M. Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy / B.M. Schaefer, V.Caracciolo, W.H. Frishman, P. Charney // Heart Dis. — 2003. — Vol. 5, N 3. — P. 202-214.
• 32. Schwartz J.B. The influence of sex on pharmacokinetics / J.B. Schwartz // Clin. Pharmacokinet. — 2003. — Vol. 42, N2. —Р. 107-121.
• 33. Shekelle P.G. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the man agement of left ventricular systolic dysfunction according to race, gender, and diabetic status / P.G. Shekelle, M.W.Rich, S.C. Morton [et al.] // J. Am. Coll. Cardiol. — 2003. — Vol. 41, N9. — P. 1529-1538.
• 34. Shen H. Aspirin Resistance in Healthy Drug-Naive Men Versus Women (from the Heredity and Phenotype Intervention Heart Study) / H. Shen, W. Herzog, M.-A. Drolet [et al.] // Amer. J. Cardiol. — 2009. — Vol. 104, Issue 4. — P. 606-612.
• 35. Stampfer M. J. Primary prevention of coronary heart disease in women through diet and lifestyle / M. J. Stampfer, F. B. Hu, J. E. Manson [et al.] // N. Engl. J. Med. — 2000. — Vol. 343, N 1. — P. 16-22.
• 36. Wood М. J. HRT to prevent cardiovascular disease: What studies show, how to advise patients / M. J. Wood, J. I. Cox // Postgraduate medicine. — 2000. — Vol. 108, N 3. — P. 59-72.

«Bulletin of problems biology and medicine» Issue 1 part 1 (126), 2016 year, 42-47 pages, index UDK 616.12-005.4-055.2